Cyclopharm

Cyclopharm Equity Ratio

The Equity Ratio of Cyclopharm (CYC.AX) as of Nov 11, 2026 is 58.81 %. In the previous year, Equity Ratio was 68.78 % — a change of -14.50% (lower).

Equity Ratio

58.81 %

YoY

-14.50%

Last updated:

Equity Ratio of Cyclopharm is 2025 58.81 % . Equity Ratio of Cyclopharm was 2024 68.78 % . It decreases by -14.50% lower compared to the previous year.

The Cyclopharm Equity Ratio history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Ratio
Date
Equity Ratio
Jan 1, 2018
72.30 AUD
Jan 1, 2019
71.33 AUD
Jan 1, 2020
60.53 AUD
Jan 1, 2021
77.26 AUD
Jan 1, 2022
73.75 AUD
Jan 1, 2023
70.26 AUD
Jan 1, 2024
68.78 AUD
Jan 1, 2025
58.81 AUD
The Cyclopharm Equity Ratio history
YEAREquity RatioYoY
58.81 %-14.50%
68.78 %-2.11%
70.26 %-4.73%
73.75 %-4.55%
77.26 %+27.64%
60.53 %-15.14%
71.33 %-1.33%
72.30 %-2.02%
73.79 %-2.81%
75.92 %-4.16%
79.21 %+11.94%
70.76 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cyclopharm Stock analysis

What does Cyclopharm do? Cyclopharm Ltd is an Australian company that was founded in 1986 and has since been developing innovative medical solutions. The company operates in the field of nuclear medicine and focuses on providing diagnostic and therapeutic products and services. The history of Cyclopharm Ltd began with the development of the Technetium-99m generator, an instrument for generating radioisotopes that can be used in medical imaging. Since then, the company has expanded its offerings and now offers a wide range of products and services. Cyclopharm Ltd's business model is based on research and development of new solutions based on the needs of the medical community and patients. The company works closely with doctors, scientists, and other experts to ensure that its products and services meet the highest standards. Cyclopharm Ltd is divided into various divisions to coordinate and optimize its activities. These include diagnostics, therapy, research and development, as well as sales and marketing. Each division works closely with the others to ensure that the company achieves its goals and provides optimal customer care. Some of Cyclopharm Ltd's most well-known products include the Technetium-99m generator and the radiopharmaceutical Technegas. Technegas is a gas used for lung imaging and plays an important role in diagnosing lung problems. The radiopharmaceutical is produced using the Technetium-99m generator and is an important addition to medical imaging. In addition, Cyclopharm Ltd also develops therapeutic solutions that can be used to treat cancer and other diseases. These include radiopharmaceuticals used in radiation therapy, as well as other solutions tailored to the individual needs of patients. Cyclopharm Ltd is also actively working on improving and expanding its products and services. The company invests in research and development to develop innovative solutions that can improve medical imaging and therapy. Additionally, the company works closely with its customers to better understand their needs and offer them tailored solutions. Overall, Cyclopharm Ltd is an innovative and goal-oriented company that focuses on providing diagnostic and therapeutic solutions in the field of nuclear medicine. The company has a long history of leadership in this field and will continue to be at the forefront of developing solutions that improve the lives of patients and medical professionals. Cyclopharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cyclopharm stock

Equity Ratio of Cyclopharm is 58.81 % in 2025.

Equity Ratio of Cyclopharm changed from 68.78 % to 58.81 %, representing a -14.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Equity Ratio Cyclopharm since 2006 – with annual values, charts, and detailed analysis.

The equity ratio measures the proportion of total assets financed by shareholders' equity. Higher ratios indicate stronger financial independence and lower leverage.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Equity Ratio's Cyclopharm with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Cyclopharm

All Key Metrics — Cyclopharm